Mo1686 COMPARATION BETWEEN DIFFERENT METHODS OF SURVEILLANCE OF DYSPLASTIC LESIONS IN PATIENTS WIHT ULCERATIVE COLITIS AND CROHN'S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

2019 ◽  
Vol 89 (6) ◽  
pp. AB521-AB522
Author(s):  
Ricardo H. Resende ◽  
Wanderlei M. Bernardo ◽  
Michele O. De Marco ◽  
Daniel T. Rezende ◽  
Raquel Cristina L. Mota ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Randomized Clinical Trials ◽  
Meta Analysis

Endpoints for Perianal Crohn’s Disease Trials: Past, Present and Future

2021 ◽  
Author(s):  
Bénédicte Caron ◽  
Ferdinando D’Amico ◽  
Silvio Danese ◽  
Laurent Peyrin-Biroulet
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Primary Endpoint ◽  
Randomized Clinical Trials ◽  
Controlled Trials ◽  
Perianal Crohn’S Disease ◽  
Perianal Crohn's Disease

Abstract Background and Aims Since the 1980s, many studies have evaluated the efficacy of therapies to improve the outcomes of patients with perianal Crohn’s disease. We performed a systematic review to describe the evolution of endpoints in perianal fistulizing Crohn’s disease. Efficacy outcomes, definitions and measurement tools were assessed. Methods Electronic databases were searched up to November 1, 2020. All published randomized placebo-controlled trials enrolling patients with perianal fistula and Crohn’s disease were eligible for inclusion. Ongoing randomized clinical trials were also described. Results Nineteen randomized controlled trials were included. Clinical efficacy endpoints were reported in all trials. Clinical response was the most frequent primary endpoint [6/19 studies, 31.6%], followed by clinical remission in four studies [21%]. Clinical response was defined as closure of at least 50% of fistulas, while remission was defined as closure of all fistulas. A combined clinical and radiological primary endpoint was used to assess fistula healing in four studies [21%]. The Perianal Disease Activity Index was a primary endpoint in only one study [5.5%]. In addition, eight ongoing controlled trials were identified. Combined clinical and radiological remission was the most frequent primary endpoint in these studies [4/8, 50%]. Conclusion In this systematic review, significant changes in outcomes used in randomized clinical trials of perianal Crohn’s disease were observed. Radiological endpoints are increasingly used in perianal fistulizing Crohn’s disease trials.

scholarly journals Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults—A Meta-Analytical Study

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2628
Author(s):  
Manuel Pabón-Carrasco ◽  
Lucia Ramirez-Baena ◽  
Samuel Vilar-Palomo ◽  
Aurora Castro-Méndez ◽  
Raúl Martos-García ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Relative Risk ◽  
Crohn's Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Unknown Etiology ◽  
Human Beings ◽  
Inflammatory Bowel

(1) Background: Inflammatory bowel diseases are pathologies of unknown etiology and auto-immune pathogenia. The use of probiotics is studied in order to increase the arsenal of treatments. The aim was to assess the efficacy of the probiotics in these diseases in the active or quiescent phases; (2) Methods: A systematic review with meta-analysis was performed by an exhaustive bibliographic search in Medline, Cinahl, Embase, Scopus, Web of Science, and Cochrane Library. The inclusion criteria were studies of more than 10 years, English/Spanish, clinical trials, and involving human beings. Relative risk was used to compare efficacy, which was meta-analyzed using a fixed effects model. Heterogeneity was evaluated with the Higgins I2 test; (3) Results: Nineteen studies were included in the systematic review and 17 in the meta-analysis, with a total of 1537 patients (nexperimental group = 762; nplacebo group = 775). There are significant remission differences in ulcerative colitis (relative risk (RR) = 0.81; 95% CI = 0.72–0.91; I2 = 32%; p = 0.16). However, no significant differences were found in the use of probiotics for the prevention of ulcerative colitis, and for the remission of Crohn’s disease; (4) Conclusions: There are data showing an additional beneficial effect of probiotics on active ulcerative colitis. More and better studies are needed which assess its possible therapeutic efficacy for quiescent ulcerative colitis and for Crohn’s disease.

Sign in / Sign up

Export Citation Format

Share Document